drugset / Trial / NCT02071810

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

NCT02071810

Phase 1 Completed 34 enrolled Bial - Portela C S.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the tolerability of BIA 9-1067 after multiple rising dose regimens of BIA 9-1067.

Timeline

Start
2008-04
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 5 mg
Subject Opicapone Small molecule 10 mg
Subject Opicapone Small molecule 20 mg
Subject Opicapone Small molecule 30 mg

Indications